On August 11, AKESO rose 3.15% in regular trading, trading at 104.2 HKD/share, with turnover of approximately 45.92 million HKD.

On the news front, the company announced that its Trop2/Nectin-4 bispecific antibody-drug conjugate (ADC) AK146D1, in combination with its core product Ivonescimab (PD-1/VEGF bispecific antibody), has completed first patient dosing in a Phase II clinical study for breast cancer treatment. This milestone marks continued execution of the company's IO2.0+ADC2.0 convergence strategy, aiming to achieve more precise anti-tumor effects through dual targeting and immune activation.

The study focuses on evaluating the safety, tolerability, and preliminary efficacy of this bispecific ADC combined with the PD-1/VEGF bispecific antibody. Notably, the same drug's Phase II study in combination with Ivonescimab for advanced non-small cell lung cancer had already completed first patient dosing in July, indicating accelerating pipeline expansion across multiple solid tumor indications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)